CYGNOS Biotech is commercializing an innovative platform of protein drugs that could have profound implications for animal and human health. Two products are currently under development, PVX – an antiviral, and MMX – an antitumor formulation.
PVX (INAD #011-949), our first investigational product, is a novel peptide derived from natural sources. It is being evaluated for the treatment of viral infections first in companion animals (dogs, cats, horses and birds). In Vitro experimentation and data from pilot animal studies suggest that PVX demonstrates antiviral activity across a broad spectrum of virus families.
MMX (INAD# 012-035) is our Company’s second investigational new drug. This formulation is being developed for the treatment of oral canine malignant melanoma stage II & III. In Vitro studies have demonstrated inhibition of cell proliferation in melanoma cells. In pilot studies with canine subjects diagnosed with malignant melanoma and treated with MMX, the subjects exhibited significant tumor reduction.
CYGNOS Biotech has been awarded a ‘Minor Use’ designation by the FDA for canine malignant melanoma to pursue a Conditional New Animal Drug Application (CNADA). The Minor Use Designation Approval is published on the FDA/CVM website. click here to visit the FDA site (then scroll to number 96) .